Digital avatar support for people having outpatient stem cell transplants
Official title: A Randomized Controlled Trial of an Avatar-based Supportive Care Intervention for Patients Undergoing Outpatient Stem Cell Transplantation
Run by Friendi.fi Corporation · NCT06564233 · Data updated 2026-11-12
This trial will test whether a conversational avatar (care.coach) can reduce anxiety and improve quality of life for adults undergoing outpatient allogeneic stem cell transplant.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Friendi.fi Corporation Industry-sponsored |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | October 21, 2024 |
| Main results expected | September 20, 2026 |
| Study ends | November 29, 2026 |
| Registry record updated | March 6, 2026 |
| Trial ID | NCT06564233 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older preparing for reduced-intensity outpatient allogeneic HCT who are fluent in English and able to interact with a digital avatar.
✕Probably not a fit
Patients who are not fluent in English or who have severe, uncorrectable hearing, vision, or speech impairments that prevent interacting with the avatar are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The program will adapt and optimize care.coach Avatar™ content and scheduling for patients receiving reduced-intensity outpatient allogeneic hematopoietic stem cell transplant (HCT). After optimization, participants will be randomized to receive the digital avatar supportive care program or usual supportive care. Primary outcomes include changes in anxiety and quality of life focused on the first 30 days after transplant, when most symptoms occur. The aim is to increase comfort with outpatient HCT and potentially expand the number of patients able to receive transplant in an outpatient setting.
Why it matters
Potential benefit: If successful, the avatar program could lower anxiety and improve quality of life after transplant and help more patients safely receive their stem cell transplants as outpatients.
How similar studies have gone: Conversational agents and digital health coaching have shown promising but mixed benefits for anxiety and quality of life in cancer populations, while their use specifically in outpatient HCT is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18+ * Seen for outpatient RIC HCT (prior to D0, generally D-6). Exclusion Criteria: * Deemed by clinical staff or research assistant (RA) to be unable to converse with an avatar, due to: severe, uncorrectable hearing or vision impairment; severe speech impairment that precludes understanding by staff (or by the avatar). * Not fluent in English.
Where it's running
-
Dana-Farber Cancer Institute
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Victor Wang, MS — Friendi.fi Corporation
- Study coordinator: Chantal M Kerssens, PhD
- Email: chantal@friendi.fi
- Phone: 404-849-8323
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Population PK-guided ATG Dosing in Haploidentical Stem Cell Transplant
This trial tests a population PK-guided ATG dosing strategy in people undergoing haploidentical hematopoietic stem cell transplantation to see if it improves outcomes.
-
Population PK-guided ATG Dosing in Haplo-HSCT
This study tests a population PK-guided dosing strategy for anti-thymocyte globulin (ATG) in adults and adolescents undergoing haploidentical stem cell transplantation to see if it can reduce GVHD while keeping relapse risk acceptable.
-
Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children
This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.
-
Personalized ATG dosing in unrelated donor stem cell transplants
This trial tests whether tailoring anti-thymocyte globulin dosing works better than standard fixed dosing in adults and adolescents receiving unrelated donor stem cell transplants.
-
Hematologic cancer survivors after stem cell transplant try a personalized care plan
This study tests a personalized Survivorship Care Plan for people with hematologic cancer who have undergone a stem cell transplant to see if it’s feasible within the Italian health system.
-
T-cell–guided letermovir stopping after allogeneic stem cell transplant
This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.